Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Non optimized vs optimized

<< Previous

Bullboard Posts

Next >>

Post by enriquesuaveon Sep 05, 2021 2:16pm

415 Views

Post# 33815697

Non optimized vs optimized

1st 12 patients undertreated by 39-85% yielded a 25% CR or 3 patients at 90 days
6 optimized treated patients yielded 67% or 4 out of 6 patients and maybe would have been 5 as one patient died after negative urinate cytology.

Hence Optimized is about 2-4 Times as likely to get CR at 90 days. IMO

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 27, 2024